Tanya Lewis

Insider Reports History

Location
Minneapolis, MN
Signature
/s/ Scott Kellen, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Tanya Lewis:

Company Role Class Num Shares Value Price $ Report Date Ownership
Replimune Group, Inc. Chief Dev. Op. Officer Common Stock 135,293 $1,477,400 $10.92 13 Jun 2023 Direct
DiaMedica Therapeutics Inc. Director Voting Common Shares, no par value per share 0 $0 $3.69 01 Jun 2025 Direct
DiaMedica Therapeutics Inc. Director Voting Common Shares, no par value per share 0 $0 $2.80 01 Jun 2024 Direct
Replimune Group, Inc. Chief Dev. Op. Officer Employee Stock Option (right to buy) 60,000 01 Apr 2023 Direct
DiaMedica Therapeutics Inc. Director Stock Option (right to buy) 32,162 01 Jun 2025 Direct

Insider Reports Filed by Tanya Lewis

Symbol Company Period Transactions Value $ Form Type Role Filing Time
DMAC DiaMedica Therapeutics Inc. 01 Jun 2025 1 $0 4 Director 03 Jun 2025, 16:17
DMAC DiaMedica Therapeutics Inc. 01 Jun 2024 1 $0 4 Director 03 Jun 2024, 16:14
REPL Replimune Group, Inc. 13 Jun 2023 2 -$309,395 4 Chief Dev. Op. Officer 15 Jun 2023, 21:01
DMAC DiaMedica Therapeutics Inc. 01 Jun 2023 1 $0 4 Director 02 Jun 2023, 16:13
REPL Replimune Group, Inc. 16 May 2023 1 -$220,336 4 Chief Dev. Op. Officer 18 May 2023, 20:34
REPL Replimune Group, Inc. 01 Apr 2023 2 $0 4 Chief Dev. Op. Officer 04 Apr 2023, 20:01
DMAC DiaMedica Therapeutics Inc. 01 Mar 2023 1 $0 4 Director 06 Mar 2023, 16:14
DMAC DiaMedica Therapeutics Inc. 01 Mar 2023 0 $0 3 Director 06 Mar 2023, 16:06
REPL Replimune Group, Inc. 16 May 2022 1 -$79,851 4 Chief Dev. Op Officer 18 May 2022, 19:02
REPL Replimune Group, Inc. 01 Apr 2022 2 $0 4 Chief Dev.Op Off 05 Apr 2022, 16:15
REPL Replimune Group, Inc. 10 May 2021 2 $0 4 Chief Dev. Oper. Off. 11 May 2021, 21:01